Secondary Screening
The market for in vitro toxicology testing is approximately $200 million and expected to grow to more than $300 million by 2005. 90% of compounds fail in drug development because of four reasons. 41% of those fail because of poor ADME; 31% because of insufficient efficacy; 22% because of toxicity; and only 6% because of market and/or commercialization complications. The earlier in the development process that an inadequate compound can be removed, the less time and money wasted, usually on the order of five to ten years and hundreds of millions of dollars.
The triage process thus represents a large opportunity with significant unmet needs, and new technologies are defining and expanding this market. Triage starts immediately after primary high-throughput screening, and the market opportunity for re-screening of hits is approximately $190 million worldwide and expected to grow to more than $250 million by 2005. The market opportunities for toxicology and ADME currently total approximately $3 billion, most of which is spent on animal studies. The market for in vitro toxicology testing, the segment within secondary screening, is approximately $200 million and expected to grow more than $300 million by 2005. The market for in vitro ADME testing represents a conversation opportunity and is forecasted to remain relatively stable.
